Juha Kiiski

Dr. Juha Kiiski

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
JKJuha Kiiski
Juha Kiiski
HKHannu O Kuokkanen
Hannu O Kuokkanen
MKMinna Kääriäinen
Minna Kääriäinen
IKIlkka S Kaartinen
Ilkka S Kaartinen
TPToni-Karri Pakarinen
Toni-Karri Pakarinen
MLMinna Katariina Laitinen
Minna Katariina Laitinen

1 September 2019 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
JKJuha Kiiski
Juha Kiiski
KRKim Räikkönen
Kim Räikkönen
MVMaarit H. Vuento
Maarit H. Vuento
MHMarja K. Hyöty
Marja K. Hyöty
JKJukka Kallio
Jukka Kallio
IKIlkka S. Kaartinen
Ilkka S. Kaartinen

HSHarri Sievänen
Harri Sievänen
MPMaarit Piirtola
Maarit Piirtola
KTKari Tokola
Kari Tokola
TKTanja Kulmala
Tanja Kulmala
ETEerika Tiirikainen
Eerika Tiirikainen
SKSaija Karinkanta
Saija Karinkanta
Whole-body vibration training (WBV) training has shown positive effects on bone strength, muscle strength, and balance, but the evidence on fall prevention is not yet persuasive. This study aimed to evaluate the effectiveness of WBV training in preventing falls and improving physical performance among older adults at fall risk. The study was an assessor- and participant-blinded, randomized, and controlled 10-week training trial with a 10-month follow-up. One hundred and thirty older adults (mean age 78.5 years, 75% women) were randomly allocated into the WBV group (n = 68) and the low-intensity wellness group (n = 62). Falls were prospectively collected using monthly returned and verified diaries. Physical performance was evaluated at baseline before randomization, after the intervention, and follow-up with established methods. The data were analyzed on an intention-to-treat basis. Negative binomial regression was used to estimate the incidence rate ratios for falls, and Cox regression models were used to calculate the hazard ratios for fallers. Between-group differences in physical performance were estimated by generalized linear mixed models. The retention rate was 93%, and the mean adherence to the WBV training was 88% and 86% to the wellness training. Sixty-eight participants fell at least once, and there were 156 falls in total. In the WBV group, the incidence rate of falls was 1.5 (95% confidence interval 0.9 to 2.5) compared to the wellness group (p = 0.11). The hazard ratio for fallers in the WBV group was 1.29 (0.78 to 2.15) (p = 0.32). There was no between-group difference in physical performance after the training period, but by the end of the follow-up, WBV-related benefits appeared. The chair-rising capacity was maintained in the WBV group, while the benefit disappeared in the wellness group (p = 0.004). Also, the 0.5-point difference in short physical performance battery (SPPB) score favored WBV training (p = 0.009). In conclusion, progressive side-alternating WBV training was feasible and well-tolerated among fall-prone older adults. During the one-year follow-up, WBV training was associated with improved physical performance but did not prevent falls compared to chair-based group exercises.

3 March 2024 in Journal of Diabetes and its Complications
Verified
Journal Article
Open access
MVMiska Vuorlaakso
Miska Vuorlaakso
VKVerna Karèn
Verna Karèn
JKJuha Kiiski
Juha Kiiski
JLJorma Lahtela
Jorma Lahtela
IKIlkka Kaartinen
Ilkka Kaartinen
Aims: Diabetic foot syndrome is a global challenge best managed through multidisciplinary collaboration. This study aimed to investigate the effect of a systematic multidisciplinary team (MDT) on the overall survival and major amputation-free survival of hospitalized patients with diabetic foot infection (DFI). Methods: This retrospective cohort study was conducted at Tampere University Hospital. Cohorts of hospitalized patients with DFI before and after the initiation of multidisciplinary wound ward were compared after an 8-year follow-up. Results: Kaplan-Meier analysis revealed significantly higher overall survival in the post-MDT cohort (37.8 % vs 22.6 %, p < 0.05) in 8-year follow-up. Similarly, major amputation-free survival was superior in this cohort (31.8 % vs 16.9 %, p < 0.05). Additionally, early major amputation was associated with inferior overall survival (35.1 % vs 12.0 %, p < 0.05). In a multivariable Cox-regression analysis cohort (hazard ratio [HR] 1.38, 95 % confidence interval [CI95%] 1.01 -1.87), early amputation (HR 1.64, CI95% 1.14 -2.34) and diagnosed peripheral artery disease (HR 2.23, CI95% 1.61 -3.09), congestive heart failure (HR 2.13, CI95% 1.47 -3.08), or moderate kidney disease (HR 1.95, CI95% 1.34 -2.84) were identified as significant risk factors affecting overall survival. Conclusions: After systematic MDT approach we found improved long-term overall and major amputation-free survival. Multidisciplinary approach is therefore highly recommended for managing patients hospitalized for DFI.

1 May 2021 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
JKJuha Kiiski
Juha Kiiski
MLMinna K. Laitinen
Minna K. Laitinen
LNLouis-Romée Le Nail
Louis-Romée Le Nail
HKHannu O. Kuokkanen
Hannu O. Kuokkanen
FPFrancis Peart
Francis Peart
MPMichael C. Parry
Michael C. Parry

16 October 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Open access
SPSusanna Pajula
Susanna Pajula
ASAnne Saarikko
Anne Saarikko
SSSinikka Suominen
Sinikka Suominen
IKIlkka Kaartinen
Ilkka Kaartinen
JKJuha Kiiski
Juha Kiiski
PHPauliina Hartiala
Pauliina Hartiala
Lymfactin® is a gene-therapy vector encoding vascular endothelial growth factor C designed to promote lymphatic vessel growth. It is administered during vascularized lymph node transfer (VLNT) to treat breast cancer-related lymphedema. This study presents the final efficacy and long-term safety results of the Lymfactin® Phase I trial. Between 2016 and 2018, 12 patients with breast cancer-related lymphedema received a therapeutic dose of Lymfactin® injected into the VLNT flap with or without autologous breast reconstruction. Patients were followed up annually for 4 years. The mean seven-day swelling volume, defined as the volume change after one week of compression interruption, decreased clearly compared to baseline at the three-year follow-up: 105.7 ±161.0 ml vs. 14.9 ± 174.2 ml. The total lymphedema quality of life (LQOLI) scores improved significantly from baseline to the three-year follow-up (p = 0.02). Within the LQOLI subdomains, physical (p < 0.01) and psychosocial (p = 0.01) scores showed significant improvement over 3 years postoperatively. Six of the 12 participants reduced or discontinued compression garment use within 3 years postoperatively. This group exhibited significantly smaller upper extremity volume differences than those who continued regular compression use (317.8 vs. 923.2 ml, p = 0.04). No serious adverse events were reported, and all the patients remained alive during the four-year follow-up. This prospective multicenter study demonstrated that Lymfactin® with VLNT is safe and well tolerated. Although volume reduction was most evident in the first year, half of the patients reduced or discontinued compression use, and quality of life improved over long-term follow up.